A Study of YL202 in Patients With Advanced Solid Tumors

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.

Trial Details

NCT ID

NCT07202364

Phase

PHASE2

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

YL202

Locations (sample)

Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Subjects must meet all the following criteria to be included in the study:
Subjects who are aware of relevant study information prior to the start of the study, and voluntarily sign and date on the informed consent form (I…
Subjects aged ≥18 years at the time of giving informed consent
Body mass index (BMI) within the range of 18 to 32 kg/m2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →